Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria
- 31 May 2025
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
Abstract
Background and Aim: This study aimed to compare the therapeutic effects and safety of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN‐TACE) and atezolizumab plus bevacizumab (Atez/Bev) as the first‐line therapies in patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond the up‐to‐seven criteria.Methods: We enrolled 768 patients with HCC treated with first‐line systemic therapy, and 154 patients were enrolled and categorized into either the LEN‐TACE therapy (n = 42) or Atez/Bev (n = 112) groups. After propensity score matching (PSM), 72 patients (LEN‐TACE group, n = 36; Atez/Bev group, n = 36) were analyzed.Results: After PSM, the median progression‐free survival showed no significant differences between the LEN‐TACE and Atez/Bev groups (8.5 [95% confidence interval (CI): 6.1–10.7] months vs. 8.6 (95% CI: 5.3–12.1) months, respectively; p = 0.973). Regarding median overall survival (OS), no significant differences were noted between the LEN‐TACE and Atez/Bev groups (37.3 [95% CI: 31.2–60.2] months vs. 32.4 (95% CI: 19.5–NE) months, respectively; p = 0.183). Regarding adverse events (AEs) of grade ≥ 3, no significant difference was observed between the two groups. Multivariate analysis revealed that the ALBI grade 1 and low AFP levels were independent factors for OS.Conclusion: LEN‐TACE therapy may be one of the effective treatment strategies in intermediate‐stage HCC patients beyond the up‐to‐seven criteria.Keywords
This publication has 24 references indexed in Scilit:
- Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patientsEuropean Journal of Cancer, 2023
- Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching AnalysisTargeted Oncology, 2022
- Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinomaScientific Reports, 2022
- Hepatocellular carcinomaThe Lancet, 2022
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 2020
- Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in JapanInvestigational New Drugs, 2019
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Hepatocellular carcinomaThe Lancet, 2018
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010